(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY(PCT)
`
`(19) World Intellectual Property Organization
`International Bureau
`
`(43) International Publication Date
`26 February 2009 (26.02.2009)
`
` (10) International Publication Number
`
`WO 2009/026197 Al
`
`(51) International Patent Classification:
`A61K 31/519 (2006.01)
`CO7D 471/04 (2006.01)
`
`(21) International Application Number:
`PC'1L/US2008/073425
`
`(22) International Filing Date: 18 August 2008 (18.08.2008)
`
`(25) Filing Language:
`
`(26) Publication Language:
`
`English
`
`English
`
`(30) Priority Data:
`60/956,744
`
`20 August 2007 (20.08.2007)
`
`US
`
`(71) Applicant (for all designated States except US): GLAXO
`GROUP LIMITED [GB/GB]; Glaxo Wellcome House,
`Berkeley Avenue, Greenford, Middlesex UB6 ONN (GB).
`
`(72)
`(75)
`
`Inventors; and
`Inventors/Applicants (for US only): DENG, Jianghe
`[CN/US]; 1250 South Collegeville Road, Collegeville,
`PA 19426 (US). LAINE, Dramane, Ibrahim [FR/US];
`709 Swedeland Road, King of Prussia, PA 19406 (US).
`PALOVICH, Michael, R.
`[US/US]; 709 Swedeland
`Road, King of Prussia, PA 19406 (US). XIE, Haibo; 1250
`South Collegeville Road, Collegeville, PA 19426 (US).
`
`(81) Designated States (unless otherwise indicated, for every
`kind of national protection available): AE, AG, AL, AM,
`AO,AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
`CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
`EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,
`IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,
`LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, Mw,
`MX, MY, MZ, NA, NG,NI, NO, NZ, OM,PG, PH, PL, PT,
`RO, RS, RU, SC, SD, SE, SG, SK, SL, SM,ST, SV, SY, TJ,
`TM,TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
`ZW.
`
`(34) Designated States (unless otherwise indicated, for every
`kind of regional protection available): ARIPO (BW, GH,
`GM, KE, LS, MW, MZ, NA, SD, SL, SZ, ‘TZ, UG, ZM,
`ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
`European (AT, BE, BG, CH, CY, CZ, DE, DK, LE, LS, II,
`ER, GB, GR, HR, HU, IK,IS, I'l, LE, LU, LV, MC, M'T, NL,
`NO,PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CE, CG,
`CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
`
`Declarations under Rule 4.17:
`
`as to applicant’s entitlement to apply for and be granted a
`patent (Rule 4.17(ii))
`as to the applicant’s entitlement to claim the priority of the
`earlier application (Rule 4.17/(iii))
`of inventorship (Rule 4.17(iv))
`
`Published:
`
`(74) Agents: KANAGY, James, M.et al.; Glaxosmithkline,
`Corporate Intellectual Property, UW 2220, 709 Swedeland
`Road, P.O. Box 1539, King of Prussia, PA 19406-0939
`(US).
`
`with international search report
`before the expiration of the time limit for amending the
`claims and to be republished in the event of receipt of
`amendments
`
`(54) Title: NOVEL CATHEPSIN C INHIBITORS AND THEIR USE
`
`‘The invention is directed to compounds
`(57) Abstract:
`according to Formula (D wherein R1, R2a, R2b, R2c, R3, and
`n are defined below, and to pharmaceutically-acceptable salts
`thereof.
`‘They are cathepsin C inhibitors and can be used in
`the treatment of diseases mediated by the cathepsin C enzyme,
`such as COPD.
`
`(R1)n
`
`N
`
`R2a
`
`R26, N
`R2c
`
`9
`i
`i
`R3
`O
`
`Formula |
`
`
`
`
`
`WO2009/026197AdTINVTMNTINEINANTINNITUMUTINYAUAA
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`NOVEL CATHEPSIN C INHIBITORS AND THEIR USE
`
`FIELD OF THE INVENTION
`
`The invention is directed to novel cathepsin C inhibitors and their use in the
`
`treatment of diseases mediated by the cathepsin C enzyme.
`
`BACKGROUND OF THE INVENTION
`
`Cathepsins are a family of enzymesincluded in the papain superfamily of cysteine
`
`proteases. Cathepsins B, C, F, H, K, L, O, S, V, W, and X have been described in the
`
`10
`
`scientific literature. Cathepsin C is also Knownin the literature as Dipeptidyl Peptidase | or
`
`"DPPI."
`
`A numberof published studies have begun to describe the role cathepsin C plays
`
`in certain inflammatory processes. See E.g. Methot et al., The Journal of Biological
`
`Chemistry, 282 (29): 20836-46 (2007); Pagano et al., Proc Nat! Acad Sci USA 104 (8):
`
`15
`
`2855-60 (2007); Xuchu Que et al., The Journal of Bioogical. Chemistry, 282 (7): 4994-
`
`5003 (2007); Adkison et al., The Journal of Clinical Investigation 109: 363-371 (2002);
`
`Tran et al., Archives of Biochemistry and Biophysics 403: 160-170 (2002); Thiele et al.,
`
`The Journal of Immunology 158: 5200-5210 (1997); Bidere et al., The Journal of Biological
`
`Chemistry 277: 32339-32347 (2002); Mabeeet al., The Journal of Immunology 160: 5880-
`
`20
`
`5885; McGuire et al., The Journal of Biological Chemistry, 268: 2458-2467; and Paris et
`
`al., FEBS Letters 369: 326-330 (1995). From these studies, it appears that cathepsin C is
`
`co-expressed with certain serine proteases, which are released from inflammatory cells
`
`recruited to sites of inflammation, and acts as a physiological activator of these proteases.
`
`Once activated, these proteases are capable of degrading various extracellular matrix
`
`25
`
`components, which can lead to tissue damage and chronic inflammation.
`
`For example, Chronic Obstructive Pulmonary Disease ("COPD")
`
`is a chronic
`
`inflammatory disease where cathepsin C is believed to play a role. The American
`
`Thoracic Society defines COPD as "a disease characterized by the presence of airflow
`
`obstruction due to chronic bronchitis or emphysema; the airflow obstruction is generally
`
`30
`
`progressive, may be accompanied by airway hyperreactivity, and may be partially
`
`reversible." American Journal of Respiratory and Critical Care Medicine 152: $77-S120
`
`(1995). Chronic bronchitis is generally characterized by a chronic productive cough,
`
`whereas emphysema is generally characterized by permanent enlargement of
`
`the
`
`airspaces distal
`
`to the terminal bronchioles and airway wall destruction.
`
`Chronic
`
`35
`
`bronchitis and emphysema usually occur together in COPD patients.
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`Cigarette smoking is a significant risk factor for developing COPD. Exposure to
`
`cigarette smoke and/or other noxious particles and gases may result
`
`in chronic
`
`inflammation of the lung.
`
`In response to such exposure, inflammatory cells such as CD8+
`
`Tcells, macrophages, and neutrophils are recruited to the area.
`
`These recruited
`
`inflammatory cells release proteases, which are believed to play a major role in the
`
`disease etiology by degrading airway walls. Proteases believed to be involved in this
`
`process include the serine proteases neutrophil elastase ("NE"), chymase ("CY"),
`
`cathepsin G, proteinase 3 and granzymes A and B. Cathepsin C appears to be involved
`
`in activating these enzymes.
`
`10
`
`15
`
`Rheumatoid arthritis
`
`("RA")
`
`is another chronic inflammatory disease where
`
`cathepsin C is believed to play a role. Arthritis and Rheumatism. 52: 2553-8 (2005).
`
`Neutrophils are recruited to the site of joint inflammation and release cathepsin G, NE,
`
`and proteinase 3, which are believd to be responsible for cartilage destruction associated
`
`with RA. Cathepsin C appears also to be involved in activating these enzymes.
`
`Other conditions where cathepsin C is believed to play a role include abdominal or
`
`thoracic aortic aneurism,
`
`adult
`
`respiratory distress
`
`syndrome,
`
`acute lung injury,
`
`osteoarthritis, asthma, multiple sclerosis, sepsis, and toxoplasmosis. See E.g. Moraes,
`
`T.J., Chow, C-W., Downey, G.P. Proteases and lung injury Critical Care Medicine 31
`
`(suppl.): S189-S194 (2003); Okayama N., Kakihana Y., Setoguchi D., Matsui K. Yuyama
`
`20
`
`N. Akaiwa M. Yoshida NL. Maeda M. Sugita Y. Izuhara K., Identification of an alternative
`
`splicing variant of cathepsin C/dipeptidyl-peptidase I, Gene 293 (1-2): 1-7 (2002); Wolters
`
`PJ. Laig-Webster M. Caughey GH., Dipeptidyl peptidase | cleaves matrix-associated
`
`proteins and is expressed mainly by mast cells in normal dog airways, American Journal
`
`of Respiratory Cell & Molecular Biology 22 (2): 183-90 (2000); Mallen-St Clair J. Pham
`
`25
`
`CT. Villalta SA. Caughey GH. Wolters PJ., Mast cell dipeptidyl peptidase | mediates
`
`survival from sepsis, Journal of Clinical Investigation 113: 628-34 (2004); Xuchu Que,
`
`Juan C. Engel, David Ferguson, Annette Wunderlich, Stanislas Tomavo, and Sharon L.
`
`Reed, Cathepsin Cs Are Key for the Intracellular Survival of the Protazoan Parasite,
`
`Toxoplasma gondii, The Journal of Biological Chemistry, 282 (7): 4994-5003 (2007).
`
`30
`
`One approach to treating these conditions is to inhibit the activity of the serine
`
`proteases involved in the inflammatory process, especially NE activity.
`
`See _E.q.,
`
`Ohbayashi, "Neutrophil elastase inhibitors as treatment for COPD", Expert Opin. Investig.
`
`Drugs 11 (7): 965-980 (2002); Shapiro, "Neutrophil Elastase: Path Clearer, Pathogen
`
`Killer, or Just Pathologic?", Am. J. Respir. Cell Mol. Biol. 26: 266-268 (2002); Imabayashi
`
`35
`
`T., Omae T., Matsunaga A., Kanmura Y., Clinical effects of a neutrophil elastase inhibitor,
`
`sivelestat,
`
`in patients with acute respiratory distress syndrome Journal of Anesthesia 20:
`
`2
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`6-70 (2006).
`
`In light of the role cathepsin C plays in activating certain serine proteases,
`
`especially NE,
`
`it is desirable to prepare compounds that inhibit its activity, which thereby
`
`inhibit serine protease activity. Thus, there is a need to identify compounds that inhibit
`
`cathepsin C, which can be usedin the treatment of a variety of conditions mediated by the
`
`cathepsin C enzyme.
`
`SUMMARYOF THE INVENTION
`
`This invention related to compounds of Formula I:
`
`N
`
`R2a
`
`(R1)n
`R2c 7] 0
`nat>/
`
`R2b
`
`N
`
`R3
`
`Ul
`O
`
`10
`
`wherein:
`
`Formula |
`
`each R1 is independently selected from the group consisting of: halo, C1-C4 alkyl,
`
`CF3, CN, NOs,
`
`-ORa,
`
`-OCF3,
`
`-C(O)NHRa,
`
`-C(OQ)ORa,
`
`-NRaRa,
`
`-NHC(O)Ra, or
`
`-
`
`NHC(O)NHRa;
`
`15
`
`n is an integer from O to 4;
`
`R2a is H, halo, -C(O)Rx, -C(OQ)ORy, -C(Q)NRaRy, -OC(O)Rx, -OC(O)NRaRy, -
`
`NRaRy, -NRaC(O)Rx, NRaC(O)R22, -NRaC(O)ORy, -NRaC(O)NRaRy, R20, R21, R22,
`
`R23, R24, -OH, -OR20, -OR21, -OR22, -OR23, or -OR24; -CN
`
`R2b is H or C1-C4 alkyl;
`
`20
`
`or R2a and R2b taken together with the carbon atom to which they are attached
`
`form a C3-C7 cycloalkyl group;
`
`R2c is H or C1-C4 alkyl;
`
`R20 is C1-C4 alkyl;
`
`wherein said R20 is optionally substituted with one or more substituents
`
`25
`
`independently selected from the group consisting of: halo, CFs, CN, NOs, R21, R22, R23,
`
`R24,
`
`-ORy,
`
`-C(O)Rx,
`
`-C(O)ORy,
`
`-C(O)NRaRy,
`
`-OC(O)Rx,
`
`-OC(O)NRaRy,
`
`-NRaRy,
`
`-
`
`NRaC(O)Rx, -NRaC(O)ORy, -NRaC(OC)NRaRy;
`
`R21 is C3-C6 cycloalkyl;
`
`wherein said R21
`
`is optionally substituted with one or more substituents
`
`30
`
`independently selected from the group consisting of: CF3, Rc, -ORa, -OCF3, and -NRaRa;
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`R22 is heterocycloalkyl;
`
`wherein said R22 is optionally substituted with one or more substituents
`
`independently selected from the group consisting of: CF3, Rc, -ORa, -OCF3, and -NRaRa;
`
`R23 is phenyl;
`
`wherein said R23 is optionally substituted with one or more substituents
`
`independently selected from the group consisting of: halo, CFs, CN, NOs, Re, -ORa, -
`
`OCF3,
`
`-C(O)Rb,
`
`-C(O)ORa,
`
`-C(O)NRaRa,
`
`-OC(O)Rb,
`
`-OC(O)NRaRa,
`
`-NRaRa,
`
`-
`
`NRaC(O)Rb, -NRaC(O)ORa, -NRaC(O)NRaRa;
`
`R24 is monocyclic heteroaryl;
`
`10
`
`wherein said R24 is optionally substituted with one or more substituents
`
`independently selected from the group consisting of: halo, CFs, CN, NOs, Rec, -ORa, -
`
`OCF3,
`
`-C(O)Rb,
`
`-C(O)ORa,
`
`-C(O)NRaRa,
`
`-OC(O)Rb,
`
`-OC(O)NRaRa,
`
`-NRaRa,
`
`-
`
`NRaC(O)Rb, -NRaC(O)ORa, -NRaC(O)NRaRa;
`
`R3 is H, R30, or R31;
`
`15
`
`R30 is C1-C4 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl;
`
`wherein said R30 is optionally substituted with one or more substituents
`
`independently selected from the group consisting of: CF3, Re, Rf, Rg, CN, -ORa, -OCFs, -
`
`ORf, -ORg, -OR31, and -NRaRa;
`
`R31 is C3-C6 cycloalkyl;
`
`20
`
`wherein said R31
`
`is optionally substituted with one or more substituents
`
`independently selected from the group consisting of: Rb, -ORa, -OCF3, and -NRaRa;
`
`each Rais independently H or C1-C4 alkyl;
`
`each Rbis independently C1-C4 alkyl;
`
`each Rcis independently C1-C4 alkyl; wherein said C1-C4 alkyl is optionally
`
`25
`
`substituted with one or more substituents independently selected from the group
`
`consisting of: CF3, -ORa, OCF3, and -NRaRa;
`
`each Rdis independently C1-C4 alkyl; wherein said C1-C4 alkyl is optionally
`
`substituted with one or more substituents independently selected from the group
`
`consisting of: CF3, -ORa, OCF3, -NRaRa, Re, and Rf;
`
`30
`
`each Reis independently phenyl or heteroaryl optionally substituted with one or
`
`more substituents independently selected from the group consisting of: halo, NOs, CFs,
`
`Rb, R23, R24, -ORa, OCF3, and -NRaRa;
`
`each Rf is independently monocyclic heteroaryl optionally substituted with one or
`
`more substituents independently selected from the group consisting of: halo, CFs, Rb,
`
`35
`
`R23, R24, -ORa, OCF3, and —-NRaRa;
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`each Rgis independently napthyl optionally substituted with one or more
`
`substituents independently selected from the group consisting of: halo, CF3, Rb, -ORa,
`
`OCF3, and -NRaRa;
`
`each Rhis independently C3-C6 cycloalkyl optionally substituted with one or more
`
`substituents independently selected from the group consisting of: Rb, -ORa, -OCFs, and —
`
`NRaRa;
`
`each Rx is Rd, Re, Rf, Rg, or Rh; and
`
`each Ryis H, Rd, Re, Rf, Rg, or Rh; or
`
`a Salt thereof.
`
`10
`
`The compounds of the invention are cathepsin C inhibitors and can be used in the
`
`treatment of diseases mediated by the cathepsin C enzyme, such as COPD. Accordingly,
`
`the invention is further directed to pharmaceutical compositions comprising a compound of
`
`the invention, or pharmaceutically acceptable salt of it. The invention is still further
`
`directed to methods of inhibiting cathepsin C and treatment of conditions associated
`
`15
`
`therewith using a compound of the invention or a pharmaceutical composition comprising
`
`a compound ofthe invention, or a pharmaceutically acceptable salt it.
`
`DETAILED DESCRIPTION OF THE INVENTION
`
`In describing the invention, chemical elements are identified in accordance with the
`
`20
`
`Periodic Table of
`
`the Elements. Abbreviations and symbols utilized herein are in
`
`accordance with the common usage of such abbreviations and symbols by thoseskilled in
`
`the chemical and biological arts.
`
`For example,
`
`the following abbreviations are used
`
`herein:
`
`“aq” is an abbreviation for aqueous
`
`25
`
`“AcCN’ is an abbreviation for acetonitrile
`
`“BOC”or “boc” is an abbreviation for tert-butyloxycarbonyl
`
`“°C” is an abbreviation for degrees Celsius
`
`“Cbz” is an abbreviation for carbobenzyloxy
`
`“CDI” is an abbreviation for carbodiimidazole
`
`30
`
`“DCM/CH2ClL“ is an abbreviation for dichloromethane
`
`“DEAD?” is an abbreviation for diethylazodicarboxylate
`
`“DMAP?” is an abbreviation for dimethylaminopyridine
`
`“DIPEA” or “DIEA”is an abbreviation for di-isopropylethylamine
`
`“DMF”is an abbreviation for dimethylformamide
`
`35
`
`“DPPA’”’is an abbreviation for diphenylphosporyl azide
`
`“EA” or “EtAc’is an abbreviation for ethyl acetate
`
`5
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`“ESI” is an abbreviation for electrospray ionization
`
`“eq” is an abbreviation for equivalent
`
`“HPLC”is an abbreviation for High Pressure Liquid Chromatography
`
`“g’ is an abbreviation for grams
`
`“h” or “hr” is an abbreviation for hour
`
`“L” is an abbreviation for liters
`
`“LC-MS”or “LC/MS”is an abbreviation for Liquid chromatography-Mass
`
`spectrometry
`
`“Me”is an abbreviation for methyl
`
`10
`
`“Ms”is an abbreviation for methanesulfonyl
`
`“mL”is an abbreviation for milliliters
`
`“min” is an abbreviation for minute or minutes
`
`“mmol” is an abbreviation for millimole or millimolar
`
`“N” is an abbreviation for Normal and refers to the number of equivalents of
`
`15
`
`reagent perliter of solution
`
`“PE”is an abbreviation for petroleum ether
`
`“Ph” is an abbreviation for phenyl
`
`“PS” is an abbreviation for polymer-supported
`
`“sat” is an abbreviation for saturated
`
`20
`
`“Si” is an abbreviation for silica
`
`“SPE”is an abbreviation for solid phase extraction
`
`“TBAF”is an abbreviation for tetra-butylammonium fluroride
`
`“TBS”is an abbreviation for t-butyldimethylsilyl
`
`“TBS-Cl” is an abbreviation for t-butyldimethyl silyl chloride
`
`25
`
`“TBTU”is an abbreviation for O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium
`
`tetrafluoroborate
`
`“TEA”is an abbreviation for triethylamine
`
`“TEMPO?”is an abbreviation for 2,2,6,6,-tetramethylpiperidine 1-oxyl
`
`“TFA” is an abbreviation for trifluoroacetic acid
`
`30
`
`“THF”is an abbreviation for tetrahydrofuran
`
`“UV”is an abbreviation for ultraviolet.
`
`“Alkyl” refers to a saturated hydrocarbon chain having the specified number of
`
`carbons. For example, C1-C8 alkyl refers to an alkyl group having from 1
`
`to 8 carbons.
`
`Alkyl groups may be optionally substituted with one or more substituents as defined
`
`35
`
`herein. Alkyl groups may be straight or branched. Representative branched alkyl groups
`
`have one,
`
`two, or three branches. Alkyl
`
`includes methyl, ethyl, propyl (n-propyl and
`
`6
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`isopropyl), butyl (n-butyl, isobutyl, and t-butyl), pentyl (n-pentyl, isopentyl, and neopentyl),
`
`and hexyl.
`
`“Alkenyl” refers to an unsaturated hydrocarbon chain having the specified number
`
`of carbons and having one at least one carbon-carbon double bond. For example, C2-C6
`
`alkenyl refers to an alkenyl group having from 2 to 6 carbons. Alkenyl groups may be
`
`optionally substituted with one or more substituent as defined herein. Alkenyl groups may
`
`be straight or branched. They, may have a cis or trans configuration. Representative
`
`branched alkenyl groups have one, two, or three branches. Alkenyl includes ethylenyl,
`
`propenyl, butenyl, pentenyl, and hexenyl.
`
`10
`
`“Alkynyl” refers to an unsaturated hydrocarbon chain having the specified number
`
`carbons and having one at least one carbon-carbon triple bond. For example, C2-C6
`
`alkynyl refers to a group having from 2 to 6 carbons. Alkynyl groups may be optionally
`
`substituted with one or more substituent as defined herein. Alkynyl groups maybestraight
`
`or branched. Alkynyl includes ethylynyl, propynyl, butynyl, pentynyl, and hexynyl.
`
`15
`
`“Aryl” refers to a monovalent aromatic hydrocarbon ring.
`
`Aryl groups are
`
`monocyclic ring systems or bicyclic ring systems. Monocyclic aryl ring refers to phenyl.
`
`Bicyclic aryl ring refers to napthyl, biphenyl, and to rings wherein phenyl
`
`is fused to a
`
`cycloalkyl or cycloalkenyl ring having 5, 6, or 7 member atoms. Aryl groups may be
`
`optionally substituted with one or more substituents as defined herein.
`
`20
`
`“Cycloalkyl” or “cycloalkenyl” refers to a saturated or unsaturated hydrocarbon
`
`ring having the specified number of carbons. For example, C3-C6 cycloalkyl refers to a
`
`cycloalkyl group having from 3 to 6 carbons. And C4-C6 cycloalkyenyl refers to a ring that
`
`has 4 to 6 carbons and at least 1 double bond. These rings are not aromatic. Either
`
`group may be optionally substituted with one or more substituents as defined herein.
`
`25
`
`Cycloalkyl
`
`includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Cycloalkenyl
`
`includes cyclobutenyl and cyclohexenyl, for example.
`
`“Enantiomerically enriched” refers to products whose enantiomeric excess is
`
`greater than zero.
`
`For example, enantiomerically enriched refers to products whose
`
`enantiomeric excess is greater than 50% ee, greater than 75% ee, and greater than 90%
`ee.
`
`30
`
`"Enantiomeric excess” or
`
`"ee" is the excess of one enantiomer over the other
`
`expressed as a percentage. As a result, since both enantiomers are present in equal
`
`amounts in a racemic mixture, the enantiomeric excess is zero (0% ee). However,if one
`
`enantiomer was enriched such that
`
`it constitutes 95% of
`
`the product,
`
`then the
`
`7
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`enantiomeric excess would be 90% ee (the amount of the enriched enantiomer, 95%,
`
`minus the amountof the other enantiomer, 5%).
`
`“Enantiomerically pure” refers to products whose enantiomeric excess is 99% ee
`
`or greater.
`
`“Half-life” ( or “half-lives”) refers to the time required for half of a quantity of a
`
`substance to be converted to another chemically distinct specie in vitro or in vivo.
`
`“Halo” refers to the halogen radical fluoro, chloro, bromo, or iodo.
`
`“Haloalkyl” refers to an alkyl group that
`
`is substituted with one or more halo
`
`substituents. Haloalkyl includestrifrouromethyl.
`
`10
`
`“Heteroaryl” refers to an aromatic ring containing from 1
`
`to 4 heteroatoms in the
`
`ring. Heteroaryl groups containing more than one heteroatom may contain different
`
`heteroatoms. Heteroaryl groups may be optionally substituted with one or more
`
`substituents as defined herein. Unless otherwise specificed, heteroaryl groups are
`
`monocyclic ring systems or are fused, spiro, or bridged bicyclic ring systems. Monocyclic
`
`15
`
`heteroaryl rings have 5 or 6 atoms. Bicyclic heteroaryl rings have from 7 to 11 atoms.
`
`Bicyclic heteroaryl
`
`rings
`
`include those rings wherein phenyl
`
`and a monocyclic
`
`heterocycloalkyl ring are attached forming a fused, spiro, or bridged bicyclic ring system,
`
`and those rings wherein a monocyclic heteroaryl
`
`ring and a monocyclic cycloalkyl,
`
`cycloalkenyl, heterocycloalkyl, or heteroaryl ring are attached forming a fused, spiro, or
`
`20
`
`bridged bicyclic ring system. Heteroaryl includes pyrrolyl, pyrazolyl,
`
`imidazolyl, oxazolyl,
`
`isoxazolyl, oxadiazolyl,
`
`thiazolyl,
`
`isothiazolyl,
`
`thiadiazolyl,
`
`furanyl,
`
`furazanyl,
`
`thienyl,
`
`triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, tetrazolyl,
`
`indolyl,
`
`isoindolyl, indolizinyl, indazolyl, purinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl,
`
`pteridinyl,
`
`cinnolinyl,
`
`benzimidazolyl,
`
`benzopyranyl,
`
`benzoxazolyl,
`
`benzisoxazolyl,
`
`25
`
`benzofuranyl,
`
`isobenzofuranyl,
`
`benzothiazolyl,
`
`benzisothiazolyl,
`
`benzothienyl,
`
`furopyridinyl, and napthyridinyl.
`
`“Heteroatom”refers to a nitrogen, sulphur, or oxygen atom.
`
`“Heterocycloalkyl” or “heterocycloalkenyl” refers to a saturated or unsaturated ring
`
`containing from 1
`
`to 4 heteroatoms atoms in the ring. These rings are not aromatic. A
`
`30
`
`ring containing more than one heteroatom may contain different heteroatoms. A ring may
`
`be optionally substituted with one or more substituent as defined herein, either on a
`
`carbon or on the heteroatom. Unless otherwise specified, these rings are monocyclic or
`
`may be fused, spiro, or a bridged bicyclic ring system. Monocyclic rings have from 5 to 7
`
`member atoms. Bicyclic rings have from 7 to 11 member atoms. Theserings include, for
`
`8
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`example,
`
`pyrrolidinyl,
`
`tetrahydrofuranyl,
`
`dihydrofuranyl,
`
`pyranyl,
`
`tetrahydropyranyl,
`
`dihydropyranyl,
`
`tetrahydrothienyl, pyrazolidinyl, oxazolidinyl,
`
`thiazolidinyl,
`
`piperidinyl,
`
`homopiperidinyl, piperazinyl, morpholinyl,
`
`thiamorpholinyl, azepinyl, 1,3-dioxolanyl, 1,3-
`
`dioxanyl,
`
`1,4-dioxanyl,
`
`1,3-oxathiolanyl,
`
`1,3-oxathianyl,
`
`1,3-dithianyl,
`
`azetidinyl,
`
`azabicylo[3.2.1Joctyl, azabicylo[3.3.1]Jnonyl, azabicylo[4.3.0]nonyl, oxabicylo[2.2.1]heptyl,
`
`and
`
`"Optionally substituted" indicates that a group, such as alkyl, alkenyl, alkynyl, aryl,
`
`cycloalkyl,
`
`cycloalkenyl, heterocycloalkyl, or heteroaryl, may be unsubstituted or
`
`substituted with one or more substituents as defined herein. "Substituted" in reference to
`
`10
`
`a group indicates that a hydrogen atom attached to a member atom within a group is
`
`replaced.
`
`It should be understood that
`
`the term "substituted" includes the implicit
`
`provision that such substitution be in accordance with the permitted valence of the
`
`substituted atom and the substituent and that the substitution results in a stable compound
`
`(i.e. one that does not spontaneously undergo transformation such as by rearrangement,
`
`15
`
`cyclization, or elimination).
`
`In certain embodiments, a single atom may be substituted with
`
`more than one substituent as long as such substitution is in accordance with the permitted
`
`valence of the atom. Suitable substituents are defined herein for each substituted or
`
`optionally substituted group.
`
`"Pharmaceutically
`
`acceptable"
`
`refers
`
`to
`
`those
`
`compounds, materials,
`
`20
`
`compositions, and dosage forms which are, within the scope of sound medical judgment,
`
`suitable for use in contact with the tissues of human beings and animals without excessive
`
`toxicity,
`
`irritation, or other problem or complication, commensurate with a reasonable
`
`benefit/risk ratio.
`
`25
`
`Compounds
`
`Compounds of particular interest herein include,
`
`in collectively or independently,
`
`the following groups:
`
`Compounds of Formula | where
`
`R1 is independently selected from the group consisting of: halo, C1-C4 alkyl, CFs,
`
`30
`
`CN, NOs, -ORa, and -OCF3;
`
`Ra is H or C1-C4alkyl;
`
`R2a is H, halo, -C(O)Rx, -C(O)ORy, or -C(O)NraRy; or
`
`R2a is -NRaRy, -NRaC(O)Rx, -NRaC(O)ORy, or -NRaC(O)NraRy; or
`
`9
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`R2a is R20, R21, R22, R23, or R24; or
`
`R2a is -OH, -OR20, -OR21, -OR22, -OR23, or -OR24;
`
`R2b is H;
`
`R2c is H;
`
`R3 is H;
`
`Rx is Rd; and
`
`Ry is phenyl optionally substituted with one or more substituents independently
`
`selected from the group consisting of: CF3, Rb, and -ORa.
`
`The compounds according to Formula | may contain one or more asymmetric
`
`10
`
`centers (also referred to as a chiral center) and may,
`
`therefore, exist as individual
`
`enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof. Chiral
`
`centers may also be present
`
`in a substituent such as an alkyl group. Where the
`
`stereochemistry of a chiral center present in Formula I, or in any chemical structure
`
`illustrated herein, is not specified the structure is intended to encompass any stereoisomer
`
`15
`
`and all mixtures thereof. Thus, compounds according to Formula | containing one or more
`
`chiral center may be used as racemic mixtures, enantiomerically enriched mixtures, or as
`
`enantiomerically pure individual stereoisomers.
`
`Individual stereoisomers of a compound according to Formula | which contain one
`
`or more asymmetric center may be resolved by methods knownto thoseskilled in the art.
`
`20
`
`For example, such resolution may be carried out (1) by formation of diasterecisomeric
`
`salts, complexes or other derivatives; (2) by selective reaction with a sterecisomer-specific
`
`reagent, for example by enzamatic oxidation or reduction; or (3) by gas-liquid or liquid
`
`chromatography in a chiral enviornment, for example, on a chiral support such as silica
`
`with a bound chiral ligand or in the presence of a chiral solvent. The skilled artisan will
`
`25
`
`appreciate that where the desired stereoisomer is converted into another chemical entity
`
`by one of the separation procedures described above, a further step is required to liberate
`
`the desired form. Alternatively, specific stereoisomers may be synthesized by asymmetric
`
`synthesis using optically active reagents,
`
`substrates, catalysts or solvents, or by
`
`converting one enantiomerto the other by asymmetric transformation.
`
`30
`
`The compounds according to Formula | may also contain double bonds or other
`
`centers of geometric asymmetry. Where the stereochemistry of a center of geometric
`
`asymmetry present in Formula I, or in any chemical structure illustrated herein,
`
`is not
`
`specified, the structure is intended to encompass the trans (E) geometric isomer, the cis
`
`(Z) geometric isomer, and all mixtures thereof.
`10
`
`If there is a cycloalkyl or cycloalkenyl
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`group present, some substituent patterns may result
`
`in and axial or an equatorial
`
`configuration. Both forms are included, unless specified otherwise.
`
`All tautomeric forms are also included in Formula | whether such tautomers exist in
`
`equilibrium or predominately in one form.
`
`In certain embodiments, compounds according to Formula | may contain an acidic
`
`functional group and are therefore capable of forming pharmaceutically-acceptable base
`
`addition salts by treatment with a suitable base.
`
`In certain other embodiments,
`
`compounds according to Formula | may contain a basic functional group and are therefore
`
`capable of forming pharmaceutically-acceptable acid addition salts by treatment with a
`
`10
`
`suitable acid. Thus, the skilled artisan will appreciate that pharmaceutically-acceptable
`
`salts of the compounds according to Formula | may be prepared.
`
`Indeed,
`
`in certain
`
`embodiments of the invention, pharmaceutically-acceptable salts of
`
`the compounds
`
`according to Formula | may be preferred over the respective free base or free acid
`
`because such salts impart greater stability or solubility to the molecule thereby facilitating
`
`15
`
`formulation into a dosage form.
`
`Accordingly,
`
`the invention is
`
`further directed to
`
`pharmaceutically-acceptable salts of the compounds according to Formula.
`
`As used herein, the term "pharmaceutically-acceptable salts" refers to salts that
`
`retain the desired biological activity of
`
`the subject compound and exhibit minimal
`
`undesired toxicological effects.
`
`These pharmaceutically-acceptable salts may be
`
`20
`
`prepared in situ during the final
`
`isolation and purification of the compound, or by
`
`separately reacting the purified compound in its free acid or free base form with a suitable
`
`baseor acid, respectively.
`
`As used herein,
`
`the term "compounds of
`
`the invention" means both the
`
`compounds according to Formula | and the pharmaceutically-acceptable salts thereof.
`
`25
`
`The term "a compound of the invention" also appears herein and refers to both a
`
`compound according to Formula | and its pharmaceutically-acceptable salts.
`
`In the solid state, compounds of the invention can exist
`
`in crystalline, semi-
`
`crystalline and amorphous forms, as well as mixtures thereof. The skilled artisan will
`
`appreciate that pharmaceutically-acceptable solvates of a compound of the invention may
`
`30
`
`be formed wherein solvent molecules are incorporated into the solid-state structure during
`
`crystallization. Solvates may involve water or nonaqueous solvents, or mixtures thereof.
`
`In addition, the solvent content of such solvates can vary in response to environment and
`
`upon storage. For example, water may displace another solvent over time depending on
`
`relative humidity and temperature.
`
`35
`
`Solvates wherein water is the solvent
`
`that
`
`is incorporated into the solid-state
`
`structure are typically referred to as "hydrates." Solvates wherein more than one solvent
`
`11
`
`

`

`WO 2009/026197
`
`PCT/US2008/073425
`
`is incorporated into the solid-state structure are typically referred to as “mixed solvates’.
`
`Solvates include “stoichiometric solvates” as well as compositions containing variable
`
`amounts of solvent (referred to as “non-stoichiometric solvates”). Stoichiometric solvates
`
`wherein water is the solventthat is incorporated into the solid-state structure are typically
`
`referred to as "stoichiometric hydrates", and non-stoichiometric solvates wherein wateris
`
`the solvent that is incorporated into the solid-state structure are typically referred to as
`
`"non-stoichiometric hydrates”.
`
`The invention includes both stoichiometric and non-
`
`stoichiometric solvates.
`
`In addition, crystalline forms of a compound of the invention,
`
`including solvates
`
`10
`
`thereof, may contain solvent molecules, which are not incorporated into the solid-state
`
`structure.
`
`For example, solvent molecules may become trapped in the crystals upon
`
`isolation.
`
`In addition, solvent molecules may be retained on the surface of the crystals.
`
`The invention includes such forms.
`
`The skilled artisan will
`
`further appreciate that compounds of
`
`the invention,
`
`15
`
`including solvates thereof, may exhibit polymorphism (i.e. the capacity to occur in different
`
`crystalline packing arrangements). These different crystalline forms are typically Known
`
`as "polymorphs." The invention includes all such polymorphs. Polymorphs have the
`
`same chemical composition but differ in packing, geometrical arrangement, and other
`
`descriptive properties of the crystalline solid state.
`
`Polymorphs,
`
`therefore, may have
`
`20
`
`different physical properties such as shape, density, hardness, deformability, stability, and
`
`dissolution properties. Polymorphs typically exhibit different IR spectra and X-ray powder
`
`diffraction patterns, which may be usedfor identification. Polymorphs may also exhibit
`
`different melting points, which may be used for identification. The skilled artisan will
`
`appreciate that different polymorphs may be produced, for example, by changing or
`
`25
`
`adjusting the reaction conditions or reagents, used in making the compound.
`
`For
`
`example, changes in temperature, pressure, or solvent may result in the production of
`
`different polymorphs.
`
`In addition, one polymorph may spontaneously convert to another
`
`polymorph under certain conditions.
`
`Methods of Use
`
`30
`
`The compounds of the invention inhibit the cathepsin C enzyme and ca

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

PTO Denying Access

Refresh this Document
Go to the Docket